Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -16.47% is 97% above its 5-year average of -497.68%, near the high end of its 5-year range (-11149.59%–19.74%).
700.70% below its 12-month average of 2.74%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 19.74%.
EBITDA MARGIN
-16.47%
EBITDA MARGIN AVG TTM
2.74%
EBITDA MARGIN AVG 3Y
-95.22%
EBITDA MARGIN AVG 5Y
-497.68%
EBITDA MARGIN AVG 10Y
-2320.94%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-700.70%
CURRENT VS 3Y AVG
+82.70%
CURRENT VS 5Y AVG
+96.69%
CURRENT VS 10Y AVG
+99.29%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Ascendis Pharma A/S
Market Cap
$14.16B
EBITDA Margin
-16.47%
TTM Avg
2.74%
3Y Avg
-95.22%
5Y Avg
-497.68%
Market Cap
$14.64B
EBITDA Margin
-11.84%
TTM Avg
-53.07%
3Y Avg
-52.51%
5Y Avg
-64.32%
Market Cap
$14.97B
EBITDA Margin
22.69%
TTM Avg
18.62%
3Y Avg
20.95%
5Y Avg
21.80%
Market Cap
$13.19B
EBITDA Margin
6.13%
TTM Avg
13.31%
3Y Avg
19.35%
5Y Avg
24.86%
Market Cap
$15.24B
EBITDA Margin
32.07%
TTM Avg
25.68%
3Y Avg
26.69%
5Y Avg
27.49%
Market Cap
$12.95B
EBITDA Margin
-111.55%
TTM Avg
-188.02%
3Y Avg
-1871.48%
5Y Avg
-2339.83%
Market Cap
$12.89B
EBITDA Margin
16.91%
TTM Avg
18.03%
3Y Avg
18.32%
5Y Avg
17.35%
Market Cap
$12.52B
EBITDA Margin
5.99%
TTM Avg
7.75%
3Y Avg
3.55%
5Y Avg
8.89%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ascendis Pharma A/S (ASND) | $14.16B | -16.47% | 2.74% | -95.22% | -497.68% |
| Tempus AI, Inc. (TEM)vs › | $14.64B | -11.84% | -53.07% | -52.51% | -64.32% |
| Exelixis, Inc. (EXEL)vs › | $14.79B | 38.84% | 34.03% | 26.26% | 22.70% |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.97B | 22.69% | 18.62% | 20.95% | 21.80% |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 6.13% | 13.31% | 19.35% | 24.86% |
| Solventum Corporation (SOLV)vs › | $15.24B | 32.07% | 25.68% | 26.69% | 27.49% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $12.95B | -111.55% | -188.02% | -1871.48% | -2339.83% |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 16.91% | 18.03% | 18.32% | 17.35% |
| Baxter International Inc. (BAX)vs › | $12.52B | 5.99% | 7.75% | 3.55% | 8.89% |
| Penumbra, Inc. (PEN)vs › | $12.49B | 14.73% | 11.96% | 9.26% | 5.60% |
Gross Margin
90.2%
EBITDA Margin
-16.5%
Operating Margin
-18.9%
Net Margin
71.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 19.74% |
| 2026-03-31 | 11.77% |
| 2025-12-31 | 5.95% |
| 2025-09-30 | 7.03% |
| 2025-06-30 | -30.78% |
| 2025-03-31 | -98.73% |
| 2024-12-31 | 2.79% |
| 2024-09-30 | -164.34% |
| 2024-06-30 | -364.58% |
| 2024-03-31 | -46.55% |
| 2023-12-31 | -23.07% |
| 2023-09-30 | -269.65% |
| 2023-06-30 | -287.39% |
| 2023-03-31 | -414.24% |
| 2022-12-31 | -637.41% |
| 2022-09-30 | -914.76% |
| 2022-06-30 | -2231.07% |
| 2022-03-31 | -1809.51% |
| 2021-12-31 | -2211.21% |
| 2021-09-30 | -8363.09% |
| 2021-06-30 | -11149.59% |
| 2021-03-31 | -16198.90% |
| 2020-12-31 | -17319.07% |
| 2020-09-30 | -2776.75% |
| 2020-06-30 | -5623.12% |
| 2020-03-31 | -3200.54% |
| 2019-12-31 | -2507.98% |
| 2019-09-30 | -2322.74% |
| 2019-06-30 | -1559.36% |
| 2019-03-31 | -1015.61% |
| 2018-12-31 | -338.60% |
| 2018-09-30 | -190265.00% |
| 2018-06-30 | -251355.56% |
| 2018-03-31 | -124914.29% |
| 2017-12-31 | -11301.07% |
| 2017-09-30 | -7208.53% |
| 2017-06-30 | -5515.09% |
| 2017-03-31 | -6288.17% |
| 2016-12-31 | -2115.15% |
| 2016-09-30 | -1523.78% |
| 2016-06-30 | -1288.64% |
| 2016-03-31 | -1409.38% |
| 2015-12-31 | -700.81% |
| 2015-09-30 | -338.78% |
| 2015-06-30 | -653.89% |
| 2015-03-31 | -362.09% |
| 2014-12-31 | -245.08% |
| 2014-09-30 | -65.05% |
| 2014-06-30 | -52.49% |
| 2014-03-31 | -9.79% |
| 2013-12-31 | 43.25% |
| 2013-09-30 | 30.78% |
| 2013-06-30 | 16.08% |
| 2013-03-31 | 16.08% |
